DGAP-News: BB Biotech AG / Key word(s): Annual Results/Dividend BB BIOTECH AG: 2021 was a difficult year for biotech equity markets - increased dividend of CHF 3.85 proposed 21.01.2022 / 07:00 The ...

The biotech industry has been a robust roller-coaster over the last half decade. The State Street SPDR S&P Biotech ETF (NYSE: ...

Technvaio forecast the global agricultural biotechnology market is expected to grow by USD 25.30 billion during 2021-2025. This marks a significant market slow down compared to the 2019 growth ...

SOMERSET, N.J.--(BUSINESS WIRE)--Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global biotechnology company developing, manufacturing and commercializing novel therapies, today ...

Welcome back to the working world, friends, I hope that you survived the return to the desk in good stead and are both warm and healthy. The current boom in COVID cases is a huge bummer, but perhaps ...

SOMERSET, N.J.--(BUSINESS WIRE)--Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global, clinical-stage biotechnology company developing and manufacturing novel therapies, today in ...

It’s the time of year when we all get a little sentimental. We’re wrapping up work so we can shift to wrapping presents for under the tree. At Fierce Biotech, it’s no different. If you don’t know me, ...

(RTTNews) - In the healthcare sector, more than 160 companies went public on the U.S. stock exchanges this year through traditional IPO. Listed below are the biotech stocks that delivered at least 200 ...

The FDA approval of Biogen's Alzheimer's disease drug Aduhelm was the biggest surprise. Several COVID-19 vaccine stocks skyrocketed well beyond expectations. Relatively few mergers and acquisitions ...

For the last few years, Hong Kong has been the preferred financial hub for many Chinese health care companies to go public and raise money from global investors. “Biotechnology is today the ...

Despite the success of COVID vaccines and medicines, the biotech sector underperformed the broader market in 2021. The Medical-Biomedical and Genetics industry declined 21.6% in 2021 against the S&P ...

Biotech investor Brad Loncar shared with Insider his 10 predictions for 2022. He expected a rebound for biotech stocks after a down year in 2021. He also predicted hot research areas, which CEOs could ...